Melody Janssen
N4 Pharma Plc., United Kingdom
Title: The future of nucleic acid vaccines and non-viral delivery systems
Biography
Biography: Melody Janssen
Abstract
Currently, there are a number of vaccine types on the market, including live-attenuated, killed, recombinant and subunit vaccines. Each of these vaccine types come with disadvantages such as safety, need of an adjuvant and the need of a cold chain. In order to overcome these shortcomings, nucleic acid vaccines, mRNA and DNA based, are gaining in popularity and starting to populate the pre-clinical and clinical pipelines.
Advantages of these types of vaccines are the potential to trigger both the cellular and humoral immune response and a more efficient manufacturing process. Despite the progress that have been made in the last years with regards to nucleic acid vaccines, in vivo stability remains an issue and a delivery system may be needed.
This keynote lecture will start off with a status quo of nucleic acids and then expand into the delivery systems, and in specific, non-viral delivery systems such as lipid nanocarriers.
The pros and cons of these vaccines and delivery systems will be presented and discussed, ending with a preview of the future of vaccines.